Basking Biosciences, Inc. Completes $5.4M Seed Financing
December 7, 2020
COLUMBUS, Ohio–(BUSINESS WIRE)–Basking Biosciences, Inc. (Basking), a privately-held biopharmaceutical company developing a next generation treatment for acute ischemic stroke (AIS) announced an initial closing of a $5.4M Seed Series financing. The investor syndicate includes Rev1 Ventures, Broadview Ventures and Viva BioInnovator. Concurrent with the financing, Ryan Helon of Rev1, Thomas Needham of Broadview and Dr. Dan Meyers have joined Basking’s Board of Directors.